MX2016013680A - Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos. - Google Patents
Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.Info
- Publication number
- MX2016013680A MX2016013680A MX2016013680A MX2016013680A MX2016013680A MX 2016013680 A MX2016013680 A MX 2016013680A MX 2016013680 A MX2016013680 A MX 2016013680A MX 2016013680 A MX2016013680 A MX 2016013680A MX 2016013680 A MX2016013680 A MX 2016013680A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- lipid storage
- storage disorders
- compositions
- treatment
- Prior art date
Links
- 230000013190 lipid storage Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000012190 activator Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000014060 Niemann-Pick disease Diseases 0.000 abstract 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 abstract 1
- 229960005520 bryostatin Drugs 0.000 abstract 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 abstract 1
- 229960005539 bryostatin 1 Drugs 0.000 abstract 1
- MJQUEDHRCUIRLF-YCVQJEHTSA-N bryostatins Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)C([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-YCVQJEHTSA-N 0.000 abstract 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461981473P | 2014-04-18 | 2014-04-18 | |
| US201461987360P | 2014-05-01 | 2014-05-01 | |
| PCT/US2015/025821 WO2015160851A1 (en) | 2014-04-18 | 2015-04-14 | Methods and compositions for treatment of lipid storage disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016013680A true MX2016013680A (es) | 2017-07-05 |
Family
ID=54321042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013680A MX2016013680A (es) | 2014-04-18 | 2015-04-14 | Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20170172978A1 (https=) |
| EP (1) | EP3131543A4 (https=) |
| JP (1) | JP2017511387A (https=) |
| KR (1) | KR20170031653A (https=) |
| CN (1) | CN107072982A (https=) |
| CA (1) | CA2946115A1 (https=) |
| IL (1) | IL248494A0 (https=) |
| MX (1) | MX2016013680A (https=) |
| WO (1) | WO2015160851A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018034318A1 (ja) | 2016-08-18 | 2018-02-22 | 国立大学法人 奈良先端科学技術大学院大学 | 免疫調節剤 |
| AU2019255739A1 (en) * | 2018-04-20 | 2020-11-12 | Biojiva Llc | Stabilized polyunsaturated compounds and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001040214A1 (en) | 1999-11-30 | 2001-06-07 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| US7256286B2 (en) | 1999-11-30 | 2007-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| KR20050094761A (ko) | 2002-07-02 | 2005-09-28 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 브리오스타틴형 화합물을 사용한 ｓＡＰＰα 분비의 증진및 인지 개선을 위한 수단으로서의 ＰＫＣ 활성화 |
| US8497385B2 (en) | 2007-08-31 | 2013-07-30 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| WO2009099563A2 (en) * | 2008-02-05 | 2009-08-13 | Blanchette Rockefeller Neurosciences Institute | Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease |
| WO2010014585A1 (en) | 2008-07-28 | 2010-02-04 | Blanchette Rockefeller Neurosciences Institute | Pkc-activating compounds for the treatment of neurodegenerative diseases |
| WO2011019763A2 (en) * | 2009-08-10 | 2011-02-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for the treatment of krabbe and other neurodegenerative diseases |
| JP6422778B2 (ja) * | 2011-11-13 | 2018-11-14 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | Ｐｋｃアクチベーターおよびその組合せ |
| EP3122351A1 (en) * | 2014-03-27 | 2017-02-01 | Daniel L. Alkon | Compositions and methods to treat niemann-pick disease |
-
2015
- 2015-04-14 CA CA2946115A patent/CA2946115A1/en not_active Abandoned
- 2015-04-14 CN CN201580032762.2A patent/CN107072982A/zh active Pending
- 2015-04-14 US US15/304,838 patent/US20170172978A1/en not_active Abandoned
- 2015-04-14 EP EP15780368.5A patent/EP3131543A4/en not_active Withdrawn
- 2015-04-14 US US14/686,711 patent/US9724328B2/en not_active Expired - Fee Related
- 2015-04-14 MX MX2016013680A patent/MX2016013680A/es unknown
- 2015-04-14 JP JP2017506619A patent/JP2017511387A/ja active Pending
- 2015-04-14 WO PCT/US2015/025821 patent/WO2015160851A1/en not_active Ceased
- 2015-04-14 KR KR1020167032127A patent/KR20170031653A/ko not_active Withdrawn
-
2016
- 2016-10-25 IL IL248494A patent/IL248494A0/en unknown
-
2019
- 2019-01-15 US US16/247,880 patent/US20190201377A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2946115A1 (en) | 2015-10-22 |
| EP3131543A1 (en) | 2017-02-22 |
| EP3131543A4 (en) | 2017-12-20 |
| IL248494A0 (en) | 2016-12-29 |
| US20170172978A1 (en) | 2017-06-22 |
| US20190201377A1 (en) | 2019-07-04 |
| US9724328B2 (en) | 2017-08-08 |
| KR20170031653A (ko) | 2017-03-21 |
| WO2015160851A1 (en) | 2015-10-22 |
| CN107072982A (zh) | 2017-08-18 |
| US20150297559A1 (en) | 2015-10-22 |
| JP2017511387A (ja) | 2017-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
| GB201318761D0 (en) | Compounds for the treatment of neuropsychiatric disorders | |
| MX365294B (es) | Inhibidores de proteína cinasa dependiente de adn. | |
| WO2015157559A3 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
| WO2014004861A3 (en) | Methods of treating pediatric metabolic syndrome | |
| BR112015022197A2 (pt) | tratamento de cataplexia | |
| EA201591403A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
| MX394763B (es) | Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina | |
| SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
| EA201490512A1 (ru) | Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека | |
| MX2015001250A (es) | Composiciones y tratamiento para enfermedades y trastornos del ojo. | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| EA201692292A1 (ru) | Соединения и композиции для стимулирования хондрогенеза | |
| MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| WO2015023691A3 (en) | 4-methylumbelliferone treatment for immune modulation | |
| EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
| PH12016501159A1 (en) | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system | |
| MX2015004389A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionadods. | |
| BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
| MX2023005014A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
| EA201790315A1 (ru) | Модуляторы x-рецепторов печени | |
| MX366829B (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
| MX2016013680A (es) | Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos. | |
| BR112013026644A2 (pt) | método para a modulação da atividade de citocina | |
| BR112015007095A2 (pt) | derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados |